Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CytoSorbentsCTSO +10.38%31 Pretax Margin % is -45.85% as of Jun. 2026. GuruFocus rates CTSO with a GF Score™ of 31/100 and a GF Value™ of $0.86 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 815 Medical Devices & Instruments companies, CytoSorbents ranks worse than 75.71% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. CytoSorbents's Pre-Tax Income for the
three
months ended in Jun. 2026 was $-4.42 Mil. CytoSorbents's Revenue for the
three
months ended in Jun. 2026 was $9.63 Mil. Therefore, CytoSorbents's pretax margin for the quarter that ended in Jun. 2026 was -45.85%.
The historical rank and industry rank for CytoSorbents's Pretax Margin % or its related term are showing as below:
CTSO'
s Pretax Margin % Range Over the Past 10 Years
Min: -147.23 Med: -78.17 Max: -22.72
Current: -50.02
CTSO's Pretax Margin % is ranked worse than 75.71% of 815
companies
in the Medical Devices & Instruments industry
Industry Median: 2.75
vs CTSO: -50.02
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
CytoSorbents Pretax Margin % Related Terms
CytoSorbents Pretax Margin % Historical Data
* Premium members only.
The historical data trend for CytoSorbents's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CTSO vs GTHP, LFWD, PETV: Pretax Margin % Comparison
For the Medical Devices subindustry, CytoSorbents's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CytoSorbents Pretax Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, CytoSorbents's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where CytoSorbents's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CytoSorbents (CTSO) has a Pretax Margin % of -45.85% as of Jun. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on CytoSorbents and its competitors. According to the industry distribution chart, CytoSorbents ranks #617 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 75.7%.
Is CytoSorbents' Pretax Margin % too high?
CytoSorbents' current Pretax Margin % is -45.85%. Based on the distribution chart, CytoSorbents ranks #617 out of 815 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, CytoSorbents has a GF Score™ of 31/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does CytoSorbents' Pretax Margin % compare to GTHP and LFWD?
According to the Medical Devices & Instruments industry distribution chart, CytoSorbents ranks #617 out of 815 companies for Pretax Margin %. This places CytoSorbents in the lower half of its industry. The industry median Pretax Margin % is 2.75. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Medical Devices & Instruments company?
The median Pretax Margin % among Medical Devices & Instruments companies is 2.75, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on CytoSorbents and its competitors. For the Medical Devices & Instruments industry, the median Pretax Margin % is 2.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CytoSorbents's current Pretax Margin % is -45.85%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CytoSorbents stock overvalued right now?
Based on GuruFocus' analysis, CytoSorbents (CTSO) is currently considered Possible Value Trap. The stock's GF Value™ is $0.86, compared to a current price of $0.40 — trading 53.5% below its estimated fair value. The current Pretax Margin % is -45.85%. CytoSorbents' overall GF Score™ is 31/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For CytoSorbents (CTSO), the current Pretax Margin % is -45.85% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CytoSorbents (CTSO) Overvalued in 2026?
Based on GuruFocus' analysis, CytoSorbents stock appears to be undervalued.
The current stock price of $0.40 is trading 53.5% below its estimated GF Value™ of $0.86.
GuruFocus considers CytoSorbents to be Possible Value Trap.
Key valuation signals for CTSO:
Pretax Margin %: -45.85%
GF Value™: $0.86 vs. price of $0.40 (53.5% below fair value)
No single metric tells the full story. See the CTSO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CytoSorbents Corp is a leader in blood purification for the treatment of life-threatening conditions in the intensive care unit and cardiac surgery. CytoSorbent's proprietary blood purification technologies are based on biocompatible, high-porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorbent's technologies are used in several broad applications. Specifically, two important applications are: the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding, and the removal of inflammatory agents and toxins in common critical illnesses that can cause massive inflammation, organ failure, and patient death. Geographically, in the USA, Germany, and Others.
31GF Score
Get the complete analysis for CTSO
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CTSO has been successfully added to your 
